European Long-acting Antipsychotics in Schizophrenia Trial
Research type
Research Study
Full title
European Long-acting Antipsychotics in Schizophrenia Trial: EULAST
IRAS ID
155550
Contact name
Thomas Barnes
Contact email
Sponsor organisation
University Medical Center Utrecht
Eudract number
2014-002765-30
Clinicaltrials.gov Identifier
Duration of Study in the UK
3 years, 9 months, days
Research summary
The main aim is to investigate the possible advantages of depot medication over oral antipsychotics in an independently designed and conducted study: a randomised, open label, multi-centre, multinational pragmatic trial. The primary objective is to compare all cause discontinuation rates in patients with schizophrenia randomised to one of two depot medications (aripiprazole depot or paliperidone palmitate) with patients randomised to one of the two oral formulations of the same medication (aripiprazole or paliperidone) over an 18-month follow-up period. Secondary objectives include differences in symptom severity, global functioning, quality of life, psychosocial functioning and side-effects, the a-priori opinion of the patients and investigators regarding the comparative values of oral vs. depot medication and safety measures.
Another component of the study (EULASTGene) is to collect blood samples from participants for genetic analysis. Genotypes associated with antipsychotic side effects will be studied, in particular metabolic syndrome and related weight gain. Genetic associations with hyperprolactinemia, movement-related adverse reactions and treatment response will also be investigated.
REC name
North West - Haydock Research Ethics Committee
REC reference
14/NW/1423
Date of REC Opinion
8 Dec 2014
REC opinion
Further Information Favourable Opinion